Commentary on "Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study"

Commentary on "Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study"

Bibliographic Details
Main Author:	Han Hyuk Lim
Format:	Article
Language:	English
Published:	Korean Society of Pediatric Endocrinology 2023-12-01
Series:	Annals of Pediatric Endocrinology & Metabolism
Online Access:	http://e-apem.org/upload/pdf/apem-2322098edi010.pdf

Similar Items

Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study
by: Ji Young Seo, et al.
Published: (2023-02-01)

The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults [version 2; peer review: 2 approved]
by: Sharon Lechtig-Wassermann, et al.
Published: (2023-12-01)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
by: Kugler AJ, et al.
Published: (2018-05-01)

Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease.
by: Sungmin Kim, et al.
Published: (2022-01-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study
by: Tomohiko Kimura, et al.
Published: (2024-01-01)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
by: Jason Seewoodhary, et al.
Published: (2010-05-01)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
by: Seewoodhary J, et al.
Published: (2010-05-01)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01)

Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide
by: David Seung U. Lee, et al.
Published: (2023-01-01)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
by: Thompson AM, et al.
Published: (2016-05-01)

EXSCEL—once-weekly exenatide reduces medical resource utilization in patients with type 2 diabetes mellitus
by: Reed, S, et al.
Published: (2018)

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
by: Juan Du, et al.
Published: (2023-01-01)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
by: Yu Su, et al.
Published: (2023-01-01)

Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
by: Paolo Basile, et al.
Published: (2023-02-01)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
by: Mann KV, et al.
Published: (2014-06-01)

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
by: Jinxin Huang, et al.
Published: (2023-05-01)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
by: Petersen AB, et al.
Published: (2013-06-01)

Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
by: Keith C. Ferdinand, et al.
Published: (2023-03-01)

Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes
by: Kerr D, et al.
Published: (2024-02-01)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
by: Maria Dolores Garcia de Lucas, et al.
Published: (2022-09-01)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
by: Saunders WB, et al.
Published: (2016-07-01)

Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: A.B.M. Kamrul-Hasan, et al.
Published: (2024-02-01)

Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
by: Becker, F, et al.
Published: (2018)

The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
by: Shuyan Gu, et al.
Published: (2024-04-01)

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
by: MacConell L, et al.
Published: (2015-05-01)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
by: Takahiro Iijima, et al.
Published: (2023-06-01)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
by: Lee J, et al.
Published: (2019-12-01)

Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
by: Sara Volpe, et al.
Published: (2022-06-01)

Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
by: Sara Volpe, et al.
Published: (2022-11-01)

Efficacy and safety of once-weekly insulin icodec compared to once-daily insulin g U-100 in patients with type II diabetes: a systematic review and meta-analysis
by: Syed Zia Saleem, et al.
Published: (2024-04-01)

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
by: Tirath Patel, et al.
Published: (2023-12-01)

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
Published: (2012-09-01)

Effects of dulaglutide on alcohol consumption during smoking cessation
by: Leila Probst, et al.
Published: (2023-11-01)

Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study
by: Virginia Bellido, et al.
Published: (2022-08-01)

Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
by: Julie Mitchell, et al.
Published: (2023-05-01)

Long‐Term Activation of Glucagon‐like peptide‐1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes
by: Saiyang Xie, et al.
Published: (2022-10-01)

Commentary on "The prevalence of diabetic peripheral neuropathy in youth with diabetes mellitus"
by: Won Kyoung Cho
Published: (2023-03-01)

Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials
by: Rodrigo Ribeiro e Silva, et al.
Published: (2023-06-01)